Canada · Delayed Price · Currency is CAD NexgenRx Statistics
Total Valuation
NexgenRx has a market cap or net worth of CAD 22.76 million. The enterprise value is 22.28 million.
| Market Cap | 22.76M |
| Enterprise Value | 22.28M |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | Dec 17, 2025 |
Share Statistics
NexgenRx has 71.12 million shares outstanding. The number of shares has increased by 8.26% in one year.
| Current Share Class | 71.12M |
| Shares Outstanding | 71.12M |
| Shares Change (YoY) | +8.26% |
| Shares Change (QoQ) | +9.54% |
| Owned by Insiders (%) | 37.18% |
| Owned by Institutions (%) | n/a |
| Float | 44.38M |
Valuation Ratios
The trailing PE ratio is 19.94.
| PE Ratio | 19.94 |
| Forward PE | n/a |
| PS Ratio | 1.28 |
| PB Ratio | 2.75 |
| P/TBV Ratio | 6.14 |
| P/FCF Ratio | 9.17 |
| P/OCF Ratio | 8.11 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.81, with an EV/FCF ratio of 8.98.
| EV / Earnings | 17.90 |
| EV / Sales | 1.26 |
| EV / EBITDA | 14.81 |
| EV / EBIT | 11.35 |
| EV / FCF | 8.98 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.11 |
| Quick Ratio | 0.11 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | 0.17 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 17.61% and return on invested capital (ROIC) is 24.33%.
| Return on Equity (ROE) | 17.61% |
| Return on Assets (ROA) | 3.47% |
| Return on Invested Capital (ROIC) | 24.33% |
| Return on Capital Employed (ROCE) | 22.61% |
| Weighted Average Cost of Capital (WACC) | 7.22% |
| Revenue Per Employee | 885,682 |
| Profits Per Employee | 62,249 |
| Employee Count | 20 |
| Asset Turnover | 0.50 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NexgenRx has paid 412,151 in taxes.
| Income Tax | 412,151 |
| Effective Tax Rate | 22.22% |
Stock Price Statistics
The stock price has increased by +23.08% in the last 52 weeks. The beta is 0.56, so NexgenRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +23.08% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.31 |
| Relative Strength Index (RSI) | 34.45 |
| Average Volume (20 Days) | 21,259 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NexgenRx had revenue of CAD 17.71 million and earned 1.24 million in profits. Earnings per share was 0.02.
| Revenue | 17.71M |
| Gross Profit | 14.41M |
| Operating Income | 1.96M |
| Pretax Income | 1.86M |
| Net Income | 1.24M |
| EBITDA | 1.39M |
| EBIT | 1.96M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 2.54 million in cash and 414,867 in debt, with a net cash position of 2.13 million or 0.03 per share.
| Cash & Cash Equivalents | 2.54M |
| Total Debt | 414,867 |
| Net Cash | 2.13M |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 8.29M |
| Book Value Per Share | 0.09 |
| Working Capital | 3.31M |
Cash Flow
In the last 12 months, operating cash flow was 2.81 million and capital expenditures -324,823, giving a free cash flow of 2.48 million.
| Operating Cash Flow | 2.81M |
| Capital Expenditures | -324,823 |
| Free Cash Flow | 2.48M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 81.33%, with operating and profit margins of 11.08% and 8.15%.
| Gross Margin | 81.33% |
| Operating Margin | 11.08% |
| Pretax Margin | 10.47% |
| Profit Margin | 8.15% |
| EBITDA Margin | 7.87% |
| EBIT Margin | 11.08% |
| FCF Margin | 14.00% |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 4.55%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 4.55% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 87.65% |
| Buyback Yield | -8.26% |
| Shareholder Yield | -3.71% |
| Earnings Yield | 5.47% |
| FCF Yield | 10.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NexgenRx has an Altman Z-Score of 1.08 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.08 |
| Piotroski F-Score | 6 |